miR-125a-3p在急性髓细胞白血病患者外周血中的表达及其意义  

The Expression and Significance of MiR-125a-3p in Peripheral Blood of Patients with Acute Myeloid Leukemia

作　　者：潘请 彭静[2] 孙晓曦[2] 戴春阳[2] 马筱玲[2] 

机构地区：[1]安徽省蚌埠医学院,233030 [2]安徽医科大学附属省立医院检验科

出　　处：《临床输血与检验》2016年第2期127-130,共4页Journal of Clinical Transfusion and Laboratory Medicine

基　　金：安徽省自然科学基金(No.1408085MH188)资助

摘　　要：目的探讨miR-125a-3p在急性髓细胞白血病（Acutemyeloidleukemia，AML）患者外周血中的表达及其意义。方法采用实时荧光定量PCR检测119例AML患者外周血标本中miR-125a-3p的表达水平，其中，初诊组53例，复发组12例，治疗组54例。另选择12例正常人作为对照。随机选择初诊组中7例患者进行外周血miR-125a-3p动态监测。结果与正常对照组比较，初诊组和复发组患者外周血miR-125a-3p的表达水平明显减低，且差异有统计学意义（P〈0．05），而治疗组患者外周血miR-125a-3p的表达水平增高，但差异无统计学意义（P〉0．05）。对初诊组和治疗组中不同FAB分型的AML患者miR-125a．3p的表达水平进行比较，发现初诊组内各型患者之间miR-125a-3p表达的差异无统计学意义（P〉0．05）；治疗组内M4型AML患者miR-125a-3p表达明显高于M0型，差异有统计学意义（P〈0．05），其他各型之间miR-125a-3p表达差异无统计学意义（P〉0．05）。7例患者miR-125a-3p动态监测结果显示，在治疗过程中，miR-125a-3p表达一直维持在较高的水平；1例患者缓解4～5个疗程后复发，其miR-125a-3p表达再次降低。结论miR-125a-3p在AML初发及复发患者外周血中低表达，诱导治疗后表达量升高，这可能与AML的发生发展有关，miR-125a-3p有望成为AML疗效评价和复发监测的生物学指标。Objective This study was to investigate the expression and significance of miR-125a-3p in peripheral blood of Acute myeloid leukemia patients. Methods Real-time fluorescent quantitative PCR was performed to detect the expression levels of miR-125a-3p in peripheral blood specimens of 119 AML patients, including 53 newly diagnosed, 12 relapsed and 54 treated patients. In addition, 12 healthy persons were selected as normal controls. Moreover, 7 persons were selected randomly from newly diagnosed patients for dynamic monitoring of miR-125a-3p levels in peripheral blood. Results Compared with normal controls, the expression levels of miR-125a-3p were decreased significantly in newly diagnosed and relapsed patients （P〈0.05）. However, miR-125a-3p expression in treated patients were increased （P〉 0.05）. The researchers compared respectively the expression levels of miR-125a-3p in different FAB subtypes of newly diagnosed and treated patients and found that there were no significant differences among various subtypes in newly diagnosed patients （P〉0.05）. In treated patients, the expression of miR-125a-3p in M4 patients was significantly higher than it in M0 （P〈0.05）, however, the differences between other subtype patients were not significant （P〉0.05）. Dynamic monitoring of miR-125a- 3p levels of 7 patients showed that miR-25a-3p expression maintained a higher level in the process of the treatment; when one patient with remission relapsed after 4-5 courses of treatment, miR-125a-3p expression reduced again. Conclusion The expression of miR-125a-3p is obviously decreased in patients with newly diagnosed and relapsed AML, and chemotherapy arises the expression level, which may be related with the occurrence and development of AML. Thus miR-125a-3p is expected to become a biological marker of AMLin evaluating for therapy efficacy and monitoring.

关 键 词：miR-125a-3p 急性髓细胞白血病 实时荧光定量PCR 动态监测 生物学指标 

分 类 号：R733.7[医药卫生—肿瘤] R392.11[医药卫生—临床医学]